News | December 30, 2021
Biological E gets nod to study Corbevax as a booster dose
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Flattish volume growth and subdued new launches were key factors for last month
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Effectiveness of Covaxin against the Omicron variant is currently being studied
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
Subscribe To Our Newsletter & Stay Updated
